SCHEMBL379947

SCHEMBL379947

Cc1ccc(-c2csc3c(-c4cccc(F)c4)cnc(NCc4ccccc4)c23)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.45
AURKB Q96GD4 7/20 0.45
PLK4 O00444 5/20 0.45
AURKA O14965 5/20 0.45
ROCK2 O75116 5/20 0.45
MAP4K4 O95819 5/20 0.45
ABL1 P00519 5/20 0.45
NTRK1 P04629 5/20 0.45
FYN P06241 5/20 0.45
CSF1R P07333 5/20 0.45
LYN P07948 5/20 0.45
MET P08581 5/20 0.45
FGFR1 P11362 5/20 0.45
FLT1 P17948 5/20 0.45
BLK P51451 5/20 0.45
NEK2 P51955 5/20 0.45
LIMK1 P53667 5/20 0.45
PTK2 Q05397 5/20 0.45
STK3 Q13188 5/20 0.45
ROCK1 Q13464 5/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379543 0.91 THRB (0.44) KDRAURKBPLK4AURKAROCK2
SCHEMBL379662 0.91 CCNC (0.49) KDRAURKBPLK4AURKAROCK2
SCHEMBL379874 0.90 CCNC (0.47) KDRAURKBPLK4AURKAROCK2
SCHEMBL380180 0.89 ESR1 (0.50) KDRAURKBFGFR1BRAFCDK8
SCHEMBL379184 0.86 KDR (0.49) KDRAURKBFYNFGFR1BRAF
SCHEMBL379876 0.86 BTK (0.47) KDRAURKBBRAFCDK8CCNC
SCHEMBL379873 0.85 PIP4K2C (0.56) KDRAURKBAURKAROCK2MAP4K4
SCHEMBL379860 0.85 CCNC (0.42) KDRAURKBPLK4AURKAROCK2
SCHEMBL379469 0.85 ESR1 (0.49) KDRAURKBPLK4AURKAROCK2
SCHEMBL379554 0.84 BRAF (0.52) KDRAURKBBRAFCDK8CCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US claimed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP claimed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP claimed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US claimed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO claimed
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 KDR 2522/4885AURKB 2258/4885PLK4 2687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.